|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||37.59 / 55.51|
Senators Grassley, Blumenthal and Klobuchar demand Mylan reduce the price of its dominant treatment for life-threatening allergies.
Iowa Senator Chuck Grassley has officially requested Myaln (MYL) explain its price increases for the EpiPen.
Prices of Mylan's (MYL) EpiPen have reportedly increased 450% since 2004.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ELP, FCB, FGBI, HMC, IRT, JACK, JCP, MYL, NMIH, OBAS, SEED Downgrades: ATNI, CXW, PFIN, RIC, WABC Initiations: None Read on to get TheStreet Quant Ratings' detailed report:
The Pittsburgh-based pharmaceutical company has been steadily jacking up the price of the auto injectors since 2010 to bolster revenues.
Despite cutting its full year guidance, the company continues to have a lot of potential upside.
Perrigo might have been in more of a decline than the market realized when it turned down Mylan's $26 billion offer for the company last year, says Jim Cramer.
Stock futures are rising on Wednesday as investors consider earnings from Disney and retailers.
Mylan (MYL) stock was trading lower after-hours on Tuesday after reporting financial results for the 2016 second quarter.
The stock should break above the resistance line on its way to its December high of around $55, if it beats earnings expectations late Tuesday.
Tennis icon Billie Jean King co-founded World Team Tennis (WTT) in 1974 and the organization's intent resonates more today than ever before with tennis fans.
The stock is breaking out of consolidation patterns on multiple timeframes.
Mylan Has Declared the Offer Unconditional, with Settlement Expected to Occur on Aug. 5, 2016
An investor should make good money on any turn in the drug maker's business or in investor sentiment.
Mylan Has Now Received All Antitrust Regulatory Clearances to Acquire Meda
TheStreet highlights 3 stocks pushing the drugs industry lower today.
The Swiss pharmaceuticals company confirms a forecast for full-year sales to increase in the low to mid-single digits, and for earnings per share to grow faster than revenue.
Trade-Ideas LLC identified Mylan (MYL) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate
The buyer agrees to asset sales to allay the antitrust concerns of Brussels regulators.
The most recent short interest data has been released for the 06/30/2016 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.